AB1502 RELIABILITY OF DAILY ELECTRONIC PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH SJÖGREN’S SYNDROME, OSTEOARTHRITIS AND PSORIATIC ARTHRITIS: THE COTIDIANA PROJECT
Authors: N. Nakhost Lotfi, H. Lechner-Radner, F. Nunes, P. Matias, R. Graca, T. Stamm, P. Studenic
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Regular and reliable assessment of different outcomes are crucial in disease management of patients with rheumatic and musculoskeletal diseases (RMDs). Remote collection of electronic patient-reported outcome measures (ePROMs) via mobile apps has emerged as meaningful in the management process of aiming to improve quality of care and, as a consequence, health related quality of life. The Cotidiana project aims to implement frequent remote monitoring by using ePROMs via a smartphone app. <h3>Objectives:</h3> We aimed to investigate the test-retest and convergent validity of daily and weekly short ePROMs collected via the app and whether frequent assessments maintain reliability across different time intervals. <h3>Methods:</h3> Adult patients (≥18yrs) with Primary Sjögren's Syndrome (PSS), Osteoarthritis (OA), and Psoriatic Arthritis (PsA) were recruited from the rheumatology division of the Medical University of Vienna. After short instructions of the "COTIDIANA" App, patients were asked to complete a total of 7 short daily as well as weekly questions (visual analogue scale [VAS] on global disease activity [PGA], pain, anxiety and depression, fatigue, and sleep) for 14 days. To assess reliability, intraclasscorrelation (ICC) of ePROs for 1-6 day test-retest intervals, as well as the smallest detectable difference (SDDs) were calculated. Further convergent validity was evaluated via correlation of daily and weekly ePROMs. <h3>Results:</h3> In total 48 patients (18 PSS, 20 PsA and 10 OA, 76.12% female) were included for analyses (Table 1). At the 1-day test-retest interval, ICCs ranged between 0.81 and 0.89 and SDDs from 1.04-2.10, for all ePRO domains. The 6-day interval presented a wider reliability range with ICCs from 0.23 to 0.73 and SDDs ranging from 1.89 to 2.88. (Figure 1A–F) While all measures demonstrated high test-retest reliability during the 1-day, 2-day and 3-day interval (ICC: 0.83 – 0.98), an increase in SDDs and a decrease in ICCs was observed as intervals extended to 6 days (Figure 1F). Daily measured ePROMs highly correlated with its respective corresponding weekly ePROM (Pain = 0.97, Anxiety and Depression=0.94, Fatigue= 0.90, Sleep= 0.95, PGA= 0.94) <h3>Conclusion:</h3> Reliability demonstrated stability, especially in shorter test-retest intervals Convergent validity was high between daily and weekly assessment. Short ePROMs collected via a smartphone app may offer the flexibility to vary time between assessment while maintaining consistent reliability. REFERENCES: NIL. <h3>Acknowledgements:</h3> We are grateful to colleagues form out outpatient clinic in assisting in facilitaiton of the study. <h3>Disclosure of Interests:</h3> Nasim Nakhost Lotfi: None declared, Helga Lechner-Radner AbbVie, Lilly, Pfizer, UCB, Janssen,, Francisco Nunes: None declared, Pedro Matias: None declared, Ricardo Graca: None declared, Tanja Stamm AbbvVe, Roche, Paul Studenic AstraZeneca, AbbVie.